Search
for
Sort by
Research 31–60 of 1000+
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Image 2_Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata.tif
- JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Montagna Symposium 2017—Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment
- 220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains
- 237 Unveiling Skin Cancers Pathophysiology via the Modeling of Xeroderma Pigmentosum Disease Modeling Using CRISPR-Cas9 Technology
- 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
- 26 Characterization of a murine model of aa induced by adoptive transfer of cultured lymph node cells
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- British Association of Dermatologists living guideline for managing people with alopecia areata 2025
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- Alopecia Areata: An Updated Review for 2023
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Abstracts from the 2024 WDS Forum - virtual option
- SnapshotDx Quiz: April 2022
- SnapshotDx Quiz: September 2018
- Registrars and Fellows Update Session 2
- PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
- SnapshotDx Quiz: March 2016
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib